NO20065730L - Nye CIS-Imidazoliner - Google Patents

Nye CIS-Imidazoliner

Info

Publication number
NO20065730L
NO20065730L NO20065730A NO20065730A NO20065730L NO 20065730 L NO20065730 L NO 20065730L NO 20065730 A NO20065730 A NO 20065730A NO 20065730 A NO20065730 A NO 20065730A NO 20065730 L NO20065730 L NO 20065730L
Authority
NO
Norway
Prior art keywords
imidazolines
new cis
cis
new
antiproiferative
Prior art date
Application number
NO20065730A
Other languages
English (en)
Norwegian (no)
Inventor
Stephen E Webber
Binh Thanh Vu
Gregory Jay Haley
Klaus B Simonsen
Nader Fotouhi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20065730L publication Critical patent/NO20065730L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26Radicals substituted by carbon atoms having three bonds to hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20065730A 2004-05-18 2006-12-12 Nye CIS-Imidazoliner NO20065730L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57227504P 2004-05-18 2004-05-18
US61553404P 2004-10-01 2004-10-01
US66877205P 2005-04-06 2005-04-06
PCT/EP2005/005046 WO2005110996A1 (en) 2004-05-18 2005-05-10 Novel cis-imidazolines

Publications (1)

Publication Number Publication Date
NO20065730L true NO20065730L (no) 2007-01-19

Family

ID=35058746

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065730A NO20065730L (no) 2004-05-18 2006-12-12 Nye CIS-Imidazoliner

Country Status (21)

Country Link
US (2) US7964724B2 (es)
EP (1) EP1753727B1 (es)
JP (1) JP4814228B2 (es)
KR (3) KR100832277B1 (es)
CN (1) CN1953965B (es)
AR (1) AR049545A1 (es)
AT (1) ATE414693T1 (es)
AU (1) AU2005243465B2 (es)
BR (1) BRPI0511328A (es)
CA (1) CA2565189A1 (es)
DE (1) DE602005011132D1 (es)
ES (1) ES2314660T3 (es)
IL (1) IL178884A (es)
MX (1) MXPA06013246A (es)
MY (1) MY143800A (es)
NO (1) NO20065730L (es)
PE (1) PE20060679A1 (es)
RU (1) RU2006144811A (es)
TW (1) TW200600501A (es)
WO (1) WO2005110996A1 (es)
ZA (1) ZA200609595B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
US7579368B2 (en) * 2005-03-16 2009-08-25 Hoffman-La Roche Inc. Cis-imidazolines
ES2538714T3 (es) * 2005-12-01 2015-06-23 F. Hoffmann-La Roche Ag Derivados de 2,4,5-trifenil-imidazolina como inhibidores de la interacción entre las proteínas p53 y MDM2 para el uso en calidad de agentes anticancerosos
WO2007082805A1 (en) 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
BRPI0713119A2 (pt) 2006-06-30 2012-04-17 Schering Corp piperidinas substituìdas que aumentam a atividade de p53 e os usos destas
WO2008065068A2 (en) * 2006-11-27 2008-06-05 Novartis Ag Substituted dihydroimidazoles and their use in the treatment of tumors
BRPI0720546A2 (pt) 2006-12-14 2015-06-23 Daiichi Sankyo Co Ltd Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
CA2939778C (en) * 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
US7625895B2 (en) * 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
RU2487127C2 (ru) 2007-10-09 2013-07-10 Ф.Хоффманн-Ля Рош Аг Хиральные цис-имидазолины
WO2009151069A1 (ja) 2008-06-12 2009-12-17 第一三共株式会社 4,7-ジアザスピロ[2.5]オクタン環構造を有するイミダゾチアゾール誘導体
DE102008047128A1 (de) 2008-09-15 2010-04-15 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung von cis-Imidazolinen, insbesondere Nutlinen, zur Behandlung von chemoresistenten Krebserkrankungen
ES2463820T3 (es) 2009-01-16 2014-05-29 Daiichi Sankyo Company, Limited Derivado de imidazotiazol que tiene estructura de anillo de prolina
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
JP2013510860A (ja) 2009-11-12 2013-03-28 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールmdm2アンタゴニスト
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2011106650A2 (en) * 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
US9266860B2 (en) 2010-09-30 2016-02-23 St. Jude Children's Research Hospital Aryl-substituted imidazoles
NZ611866A (en) 2010-11-12 2015-04-24 Univ Michigan Spiro-oxindole mdm2 antagonists
DK2684880T3 (en) 2011-03-10 2018-05-22 Daiichi Sankyo Co Ltd DISPIROPYRROLIDINE DERIVATIVES
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールmdm2アンタゴニスト
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
WO2013054153A1 (en) 2011-10-11 2013-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Nutlin compounds for use in he treatment of pulmonary hypertension
WO2013059525A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
US8987274B2 (en) 2011-10-28 2015-03-24 Merck Sharp & Dohme Corp Macrocycles that increase p53 activity and the uses thereof
JP5992054B2 (ja) 2011-11-29 2016-09-14 ノバルティス アーゲー ピラゾロピロリジン化合物
US9062071B2 (en) 2011-12-21 2015-06-23 Merck Sharp & Dohme Corp. Substituted piperidines as HDM2 inhibitors
JO3357B1 (ar) 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
SG11201404648PA (en) 2012-02-15 2014-09-26 Aileron Therapeutics Inc Peptidomimetic macrocycles
CN108912211A (zh) 2012-02-15 2018-11-30 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
AU2014223547B2 (en) 2013-02-28 2017-11-16 Amgen Inc. A benzoic acid derivative MDM2 inhibitor for the treatment of cancer
AU2014236812B2 (en) 2013-03-14 2018-03-01 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
WO2014165816A1 (en) 2013-04-05 2014-10-09 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016344A (es) 2013-05-27 2016-03-01 Novartis Ag Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
EA028175B1 (ru) 2013-05-28 2017-10-31 Новартис Аг Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
MX2015016425A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
CN104208066B (zh) * 2013-06-03 2016-06-15 中国科学院遗传与发育生物学研究所 哌嗪衍生物作为p53分子调节剂的用途
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
EA029269B1 (ru) 2013-11-21 2018-02-28 Новартис Аг Производные пирролопирролона и их применение для лечения заболеваний
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
BR112017005736A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e formulações dos mesmos
RS58961B1 (sr) 2015-01-22 2019-08-30 Sanofi Aventis Deutschland Proces proizvodnje 2-[4-(ciklopropankarbonil)fenil]-2-metil-propannitrila
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
RU2743432C2 (ru) 2016-04-06 2021-02-18 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Деструкторы белка mdm2
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
US20210198223A1 (en) * 2017-10-20 2021-07-01 Corbus Pharmaceuticals, Inc. Methods and compositions relating to ultrapure 5-(1,1-dimethylheptyl)-resorcinol
SG11202103282YA (en) 2018-10-08 2021-04-29 Univ Michigan Regents Small molecule mdm2 protein degraders
JP2023518423A (ja) 2020-03-19 2023-05-01 カイメラ セラピューティクス, インコーポレイテッド Mdm2分解剤およびそれらの使用
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
US11548866B1 (en) 2021-11-22 2023-01-10 Ligature Therapeutics Pte. Ltd. Therapeutic compounds and methods of use thereof
US11504381B1 (en) * 2021-11-22 2022-11-22 Ligature Therapeutics Pte. Ltd. Therapeutic compounds and methods of use thereof
KR20230087856A (ko) 2021-12-10 2023-06-19 교촌 에프 앤 비(주) 생체이용율과 이미다졸 펩타이드가 증가된 수용성 닭가슴살 가수분해물 및 그 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02101065A (ja) 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
DE4203547A1 (de) * 1992-02-07 1993-08-12 Knoll Ag Verfahren zur racemattrennung von verapamil
FR2756560A1 (fr) * 1996-12-04 1998-06-05 Adir Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB2351082A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines
US6653501B2 (en) * 2001-06-27 2003-11-25 Napro Biotherapeutics, Inc. Chiral resolution method for producing compounds useful in the synthesis of taxanes
DE60225719T2 (de) * 2001-12-18 2009-04-23 F. Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
CA2468783A1 (en) * 2001-12-18 2003-06-26 F. Hoffmann-La Roche Ag Cis-imidazolines as mdm2 inhibitors

Also Published As

Publication number Publication date
PE20060679A1 (es) 2006-08-11
KR20080027969A (ko) 2008-03-28
KR100832277B1 (ko) 2008-05-26
JP4814228B2 (ja) 2011-11-16
CN1953965B (zh) 2012-07-04
CN1953965A (zh) 2007-04-25
US20090143364A1 (en) 2009-06-04
KR20070011516A (ko) 2007-01-24
EP1753727B1 (en) 2008-11-19
ES2314660T3 (es) 2009-03-16
DE602005011132D1 (de) 2009-01-02
MXPA06013246A (es) 2007-02-08
CA2565189A1 (en) 2005-11-24
ZA200609595B (en) 2008-06-25
TW200600501A (en) 2006-01-01
AR049545A1 (es) 2006-08-16
US20050288287A1 (en) 2005-12-29
KR20110033964A (ko) 2011-04-01
EP1753727A1 (en) 2007-02-21
ATE414693T1 (de) 2008-12-15
AU2005243465B2 (en) 2011-08-25
MY143800A (en) 2011-07-15
JP2007538022A (ja) 2007-12-27
RU2006144811A (ru) 2008-06-27
US7964724B2 (en) 2011-06-21
WO2005110996A1 (en) 2005-11-24
IL178884A (en) 2010-12-30
IL178884A0 (en) 2007-03-08
BRPI0511328A (pt) 2007-12-04
AU2005243465A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
NO20065730L (no) Nye CIS-Imidazoliner
PA8561901A1 (es) Cis-imidazolinas
MXPA04005880A (es) Cis-imidazolinas como inhibidores de la mdm2.
CR20110221A (es) Terapia de combinación con péptidos epoxicetonas peptídicas
MX2009011019A (es) Difenil-dihidro-imidazopiridinonas.
ECSP066753A (es) Antagonistas del receptor de quimiocina
CY1112550T1 (el) Παραγωγο δικυκλοεστερα
ATE548031T1 (de) Inhibitoren gegen die produktion und freisetzung entzündungfördernder zytokine
GT200000002AA (es) Ureas difenilicias x-carboxiaril sustituidas como inhibidores de raf quinasa
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
NO20062198L (no) Bradykinin B1 reseptorantagonister
DOP2006000234A (es) Inhibidores de cinasa
ATE477805T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
CY1108599T1 (el) Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
DOP2006000233A (es) Inhibidores de cinasa
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
DE602005027231D1 (de) Cylglycerolen und therapeutischen verwendungen derselben
ATE412005T1 (de) Zyklosporinanalog
DE60208180D1 (de) Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung
ATE465729T1 (de) Cis-imidazoline als mdm2-hemmer
NO20030931L (no) Cefalosporin-antibiotika og prodruger derav
TW200510387A (en) Cis-2, 4, 5-triaryl-imidazolines
PT1180094E (pt) Aminoacidos policiclicos fundidos como agentes farmaceuticos
NO20045442L (no) Cykliske peptidiske antibiotika

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application